CN1954211A - 用于评估突发性大脑放电的免疫吸附剂血液测试 - Google Patents

用于评估突发性大脑放电的免疫吸附剂血液测试 Download PDF

Info

Publication number
CN1954211A
CN1954211A CNA2004800399514A CN200480039951A CN1954211A CN 1954211 A CN1954211 A CN 1954211A CN A2004800399514 A CNA2004800399514 A CN A2004800399514A CN 200480039951 A CN200480039951 A CN 200480039951A CN 1954211 A CN1954211 A CN 1954211A
Authority
CN
China
Prior art keywords
glur1
epilepsy
antibody
patient
fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2004800399514A
Other languages
English (en)
Chinese (zh)
Inventor
S·A·达姆比诺瓦
G·伊茨克诺瓦
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GRACE Laboratories LLC
Original Assignee
GRACE Laboratories LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GRACE Laboratories LLC filed Critical GRACE Laboratories LLC
Publication of CN1954211A publication Critical patent/CN1954211A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2857—Seizure disorders; Epilepsy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Addiction (AREA)
  • Rehabilitation Therapy (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Peptides Or Proteins (AREA)
CNA2004800399514A 2003-11-06 2004-11-08 用于评估突发性大脑放电的免疫吸附剂血液测试 Pending CN1954211A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US51767103P 2003-11-06 2003-11-06
US60/517,671 2003-11-06

Publications (1)

Publication Number Publication Date
CN1954211A true CN1954211A (zh) 2007-04-25

Family

ID=34590180

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2004800399514A Pending CN1954211A (zh) 2003-11-06 2004-11-08 用于评估突发性大脑放电的免疫吸附剂血液测试

Country Status (10)

Country Link
US (1) US7820398B2 (enExample)
EP (1) EP1689288B1 (enExample)
JP (1) JP4838140B2 (enExample)
CN (1) CN1954211A (enExample)
AT (1) ATE465412T1 (enExample)
AU (1) AU2004288717A1 (enExample)
CA (1) CA2585876A1 (enExample)
DE (1) DE602004026767D1 (enExample)
EA (1) EA200600920A1 (enExample)
WO (1) WO2005046442A2 (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6896872B2 (en) * 2001-06-27 2005-05-24 Svetlana A. Dambinova Rapid multiple panel of biomarkers in laboratory blood tests for TIA/stroke
US20060257943A1 (en) * 2005-01-25 2006-11-16 Cis Biotech, Inc. Ischemic biomarkers and their use to predict adverse neurological events from surgery
WO2006135893A2 (en) * 2005-06-13 2006-12-21 Cis Biotech, Inc. Methods for diagnosing and treating cerebrovascular events based on nr2 peptides
US8536115B2 (en) 2006-08-31 2013-09-17 Centre For Addiction And Mental Health Compositions and methods for modulating AMPA receptor-mediated excitotoxicity
WO2013102264A1 (en) * 2012-01-04 2013-07-11 Centre For Addiction And Mental Health Compositions and methods for modulating ampa receptor-mediated excitotoxicity
US10610861B2 (en) 2012-12-17 2020-04-07 Accellix Ltd. Systems, compositions and methods for detecting a biological condition
WO2014097286A1 (en) 2012-12-17 2014-06-26 Leukodx, Ltd. Systems and methods for determining a chemical state
US9759722B2 (en) * 2012-12-17 2017-09-12 Leukodx Ltd. Systems and methods for determining a chemical state
EP2863231A1 (en) * 2013-10-17 2015-04-22 Institut D'Investigaciones Biomédiques August Pi i Sunyer Diagnostic method for detecting a GABA(A) related autoimmune disease and related subject-matter
US10194829B2 (en) 2015-07-07 2019-02-05 Q Bio, Inc. Fast scanning based on magnetic resonance history
US9958521B2 (en) 2015-07-07 2018-05-01 Q Bio, Inc. Field-invariant quantitative magnetic-resonance signatures
US9665734B2 (en) 2015-09-12 2017-05-30 Q Bio, Inc. Uniform-frequency records with obscured context
US10964412B2 (en) 2015-10-20 2021-03-30 Q Bio, Inc. Population-based medical rules via anonymous sharing
US10359486B2 (en) 2016-04-03 2019-07-23 Q Bio, Inc. Rapid determination of a relaxation time
US10222441B2 (en) 2016-04-03 2019-03-05 Q Bio, Inc. Tensor field mapping
WO2018144044A1 (en) * 2017-02-03 2018-08-09 Q Bio, Inc. lTERATIVE MEDICAL TESTING OF BIOLOGICAL SAMPLES
US11650195B2 (en) 2017-02-03 2023-05-16 Q Bio, Inc. Iterative medical testing of biological samples
US10936180B2 (en) 2017-03-16 2021-03-02 Q Bio, Inc. User interface for medical information
US11360166B2 (en) 2019-02-15 2022-06-14 Q Bio, Inc Tensor field mapping with magnetostatic constraint
US11354586B2 (en) 2019-02-15 2022-06-07 Q Bio, Inc. Model parameter determination using a predictive model
CN113631924A (zh) 2019-05-24 2021-11-09 富士瑞必欧株式会社 甲状腺球蛋白的测定方法和测定试剂
US12320880B2 (en) 2019-09-27 2025-06-03 Q Bio, Inc. Maxwell parallel imaging
CN114514427A (zh) 2019-09-27 2022-05-17 富士瑞必欧株式会社 乙型肝炎病毒核心相关抗原的免疫测定和用于其的试剂盒
WO2021062154A1 (en) 2019-09-27 2021-04-01 Q Bio, Inc. Maxwell parallel imaging
US11614509B2 (en) 2019-09-27 2023-03-28 Q Bio, Inc. Maxwell parallel imaging
CN115335700A (zh) 2020-03-31 2022-11-11 富士瑞必欧株式会社 血中β淀粉样蛋白的免疫测定方法及用于该方法的试剂盒
CN117616277A (zh) 2021-08-06 2024-02-27 株式会社先端生命科学研究所 甲状腺球蛋白的免疫检测及用于其的试剂盒
US11614508B1 (en) 2021-10-25 2023-03-28 Q Bio, Inc. Sparse representation of measurements

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4879289A (en) * 1988-05-24 1989-11-07 Marion Laboratories, Inc. Method of ameliorating epileptic seizures
EP0497884B1 (en) * 1989-10-27 2004-04-28 The Salk Institute For Biological Studies Glutamate receptor compositions and methods
DE69128642T2 (de) 1991-06-26 1998-08-06 Dies Ooo Immunadsorbens zur diagnose von epilepsie und der risikogruppe
WO1994006345A2 (en) 1992-09-11 1994-03-31 Dambinova Svetlana Alexandrovn Immunosorbent for use in the diagnosis of neuro-psychological disorders, and use thereof
RU2112243C1 (ru) 1995-11-29 1998-05-27 Светлана Александровна Дамбинова Набор "па-тест" для диагностики неврологических заболеваний
US6896872B2 (en) * 2001-06-27 2005-05-24 Svetlana A. Dambinova Rapid multiple panel of biomarkers in laboratory blood tests for TIA/stroke
US20050233390A1 (en) * 2003-04-09 2005-10-20 Allen John W Device including a proteinaceous factor, a recombinant proteinaceous factor, and a nucleotide sequence encoding the proteinaceous factor
US20060257943A1 (en) * 2005-01-25 2006-11-16 Cis Biotech, Inc. Ischemic biomarkers and their use to predict adverse neurological events from surgery

Also Published As

Publication number Publication date
US20050181466A1 (en) 2005-08-18
ATE465412T1 (de) 2010-05-15
WO2005046442A2 (en) 2005-05-26
EP1689288A4 (en) 2007-09-26
AU2004288717A2 (en) 2005-05-26
AU2004288717A1 (en) 2005-05-26
US7820398B2 (en) 2010-10-26
EA200600920A1 (ru) 2007-04-27
DE602004026767D1 (de) 2010-06-02
JP4838140B2 (ja) 2011-12-14
JP2007517188A (ja) 2007-06-28
CA2585876A1 (en) 2005-05-26
WO2005046442A3 (en) 2006-12-07
EP1689288B1 (en) 2010-04-21
EP1689288A2 (en) 2006-08-16

Similar Documents

Publication Publication Date Title
CN1954211A (zh) 用于评估突发性大脑放电的免疫吸附剂血液测试
US12461112B2 (en) Biomarker levels and neuroimaging for detecting, monitoring and treating brain injury or trauma
EP1739430B1 (en) Assay method for cardiovascular disease
Cortese et al. Attention-deficit/hyperactivity disorder, iron deficiency, and obesity: is there a link?
US10509033B2 (en) Method, kit and biomarker for diagnosing chronic inflammatory demyelinating polyneuropathy
RU2435165C2 (ru) Биомаркеры ишемии и их применение для прогнозирования неблагоприятных неврологических последствий хирургической операции
JP4624559B2 (ja) 初期ｃｎｓダメージのマーカーとしてのタウ
Cetin et al. Serum levels of glial fibrillary acidic protein and Nogo-A in children with autism spectrum disorders
Abdul‐Rahman et al. The potential of phosphorylated α‐synuclein as a biomarker for the diagnosis and monitoring of multiple system atrophy
EP2924437B1 (en) Method for detecting neurological disease accompanied by inflammation and/or demyelination
Horellou et al. Early blood neurofilament light chain and myelin oligodendrocyte glycoprotein antibody levels associate with different disease courses of myelin oligodendrocyte glycoprotein-associated disease in children
US20060281135A1 (en) Methods for diagnosing and treating cerebrovascular events based on NR2 peptides
JP7461037B2 (ja) 睡眠障害を判定するためのバイオマーカー
US11609236B2 (en) Blood biomarkers for severe traumatic brain injuries
Abd El-Aziz et al. Serum neuron-specific enolase: a marker for neuronal injury in children with convulsive status epilepticus
JP2020153832A (ja) オートタキシン測定による神経障害性疼痛を検出する方法及び検出試薬
WO2002037105A1 (en) Diagnostic kit for schizophrenia
US20230273220A1 (en) Methods for prediction, detection and monitoring of substanceuse disorders and/or an infection
RU2648515C1 (ru) Прогнозирование течения и исхода комы и посткоматозных бессознательных состояний (в том числе вегетативных) с помощью гемотестов
RU2531922C2 (ru) Способ молекулярной диагностики состояния психосоматических функций у пациентов с дисциркуляторной энцефалопатией
Fronda The role of antibody testing for anti-natalizumab and anti-aquaporin-4 antibodies in demyelinating disorders
JP2011191057A (ja) うつ病予備群の判定方法

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20070425